Convergence Innovation™ for Bioscience is based on fundamental and applied molecular biology research and state-of-the-art capabilities. The Company has focused on the full array of genomics, including human, viral and cancer DNA, RNAs (non-coding, microRNA, snoRNA, etc.), hormone, enzyme, cell biology, signaling mechanisms, aging and degeneration, immunology, inflammatory cascade mechanisms, microbiota, and other microbiological systems diseases (including cancers, neurological and hereditary indications).
Many of these capabilities and resources are based in laboratories affiliated the Company’s bioscience ventures, and from its strategic collaborations with the Empire State Center of Excellence for Cancer Genomics at the University at Albany, New York.
In addition, NRS has actively led a genetic therapy entity and provided strategic and technical support to functional food, infectious disease, neurofeedback, autoimmune and animal health entities.
Key capabilities that NRS has secured for Bioscience and which support its NRS Convergence Innovation™ method include:
Leading researchers in cancer genomics, epigenomics, microbiomes, disease and inflammatory pathways, RNAs, exosomes, deep insights into metabolic indications and non-communicable diseases, neuroscience and degenerative disease expertise, circadian cycles analytics, nano-delivery systems, immune-system modeling, stem cell genomics, infectious diseases and viral vectors expertise;
Clinical sites for trial subject sample collection and analysis, including biostatistical computation, classification of complex data, data sets curation and quality controlling;
Instrumentation, including next generation sequencing and microscopic tools, gene-arrays, measurement and identification systems, and genetic (actual and synthetic) nucleic acid synthesis technologies;
Bioethics, clinical trial design expertise, Institutional Review Board (“IRB”) management, clinical protocol expertise, peer-review capabilities, regulatory management, clinical site management, and clinical data safety expertise;
Submission and publication of peer-reviewed methods and outcomes to leading scientific and medical journals, access to research consortia, specialized seminars and other means to become alerted to next-generation technologies;
Techniques and instrumentation for analyzing various CRISPR system off-target effects, and integration site analysis for other genetic insertional applications;
Technical writing, including patent applications, grant writing and submissions to other capital and resource awarding research entities; and,
SOPs for highly regulated laboratory operations, such as CLIA and CLEP, and access to leading principal investigators with whom multi-center clinical trials can be arranged.